NICE: Terminated appraisal for Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

NICE  published today, 29 November 2023,  the conclusion of the appraisal for Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies, Technology appraisal [TA933] with the following Advice:

NICE is unable to make a recommendation about the use in the NHS of tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. Novartis has agreed with NICE and NHS England that a guidance update would not be a productive use of resources. Novartis considers that changes to treatment and reimbursement mean that the submission would not be viable within what NICE considers a cost-effective use of NHS resources.

NICE and the company have considered all the options for producing guidance on tisagenlecleucel for this indication. The decision to terminate this appraisal has not been taken lightly. NICE is disappointed that the committee and stakeholders will not have the opportunity to fully review the new evidence collected.

For data collected when this technology was in the Cancer Drugs Fund (NICE's technology appraisal guidance 567), see the National Disease Registration Service's data review on tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma. Data from the Novartis JULIET clinical trial will be published on the NICE website when available.

additional information available at this link